40 research outputs found
Active Enhancement of Rat Cardiac Allografts by Donor-Specific B Lymphocytes
In an attempt to induce the active enhancement of the cardiac allografts, recipient rats were injected intravenously with 1 x 107 donor-specific spleen cells or an equal number of their T or B cell subpopulations on each of 7 days before transplantation. Mean survival times (MST) in the group pretreated with donor-specific spleen cells (MST 27.5 ± 7.8 days) and the group pretreated with donor-specific B cells (MST 37.5 ± 15.5 days) were significantly prolonged (p<0.01) compared with the untreated control (MST 11.6 ± 2.0 days) and the group pretreated with donor-specific T cells. To investigate the mechanisms of the beneficial effect of donor-specific B cells on rat cardiac allografts, inhibition assay of mixed lymphocyte reaction (MLR) were carried out by the addition of recipient rat sera or spleen cells harvested 7 days following the intravenous administration of donor-specific spleen cells or their T and B cell subpopulations. Recipient rat sera harvested 7 days following the intravenous administration of donor-specific B cells showed significant inhibition of MLR; this inhibition was correlated to the prolonged survival of histoincompatible rat cardiac allografts. In contrast, MLR suppressor cells could not be detected in any experimental group. Thus, donor-specific B cell given 7 days before transplantation may possibly have beneficial effect on rat cardiac allografts and MLR inhibition induced by the intravenous administration of donor-specific B cells may be essential for prolonged allograft survival
Age, gender, insulin and blood glucose control status alter the risk of ischemic heart disease and stroke among elderly diabetic patients
<p>Abstract</p> <p>Background</p> <p>We analyzed the effects of insulin therapy, age and gender on the risk of ischemic heart disease (IHD) and cerebrovascular accident (CVA) according to glycemic control.</p> <p>Methods and Results</p> <p>We performed a prospective cohort study (Japan Cholesterol and Diabetes Mellitus Study) of type 2 diabetes patients (n = 4014) for 2 years. The primary endpoint was the onset of fatal/non-fatal IHD and/or CVA, which occurred at rates of 7.9 and 7.2 per 1000 person-years, respectively. We divided diabetic patients into four groups based on age (†70 and > 70) and hemoglobin A1C levels (†7.0 and > 7.0%). Multiple regression analysis revealed that IHD was associated with high systolic blood pressure and low HDL-C in patients under 70 years of age with fair glycemic control and was associated with low diastolic blood pressure in the older/fair group. Interestingly, insulin use was associated with IHD in the older/poor group (OR = 2.27, 95% CI = 1.11-5.89; p = 0.026) and was associated with CVA in the older/fair group (OR = 2.09, 95% CI = 1.06-4.25; p = 0.028). CVA was associated with lower HDL-C and longer duration of diabetes in younger/poor glycemic control group. Results by stepwise analysis were similar. Next, patients were divided into four groups based on gender and diabetic control(hemoglobinA1C < or > 7.0%). Multiple regression analysis revealed that IHD was associated with high systolic blood pressure in male/fair glycemic control group, age in male/poor control group, and short duration of diabetic history in females in both glycemic control groups. Interestingly, insulin use was associated with IHD in the male/poor group(OR = 4.11, 95% CI = 1.22-8.12; p = 0.018) and with CVA in the female/poor group(OR = 3.26, 95% CI = 1.12-6.24; p = 0.02). CVA was associated with short duration of diabetes in both female groups.</p> <p>Conclusions</p> <p>IHD and CVA risks are affected by specific factors in diabetics, such as treatment, gender and age. Specifically, insulin use has a potential role in preventing IHD but may also be a risk factor for CVA among the diabetic elderly, thus revealing a need to develop improved treatment strategies for diabetes in elderly patients. The Japan Cholesterol and Diabetes Mellitus Study was formulated to evaluate them(Umin Clinical Trials Registry, clinical trial reg. no. UMIN00000516; <url>http://www.umin.ac.jp/ctr/index.htm</url>).</p
Omentin Prevents Myocardial Ischemic Injury Through AMP-Activated Protein Kinase- and Akt-Dependent Mechanisms
ObjectivesThis study examined the impact of omentin on myocardial injury in a mouse model of ischemia/reperfusion (I/R) and explored its underlying mechanisms.BackgroundObesity is a major risk factor for ischemic heart disease. Omentin is a circulating adipokine that is down-regulated by obesity.MethodsIn patients who underwent successful reperfusion treatment after acute myocardial infarction, cardiac function and perfusion defect were assessed by using scintigraphic images. Mice were subjected to myocardial ischemia followed by reperfusion.ResultsThis study found that high levels of plasma omentin were associated with improvement of heart damage and function after reperfusion therapy in patients with acute myocardial infarction. Systemic administration of human omentin to mice led to a reduction in myocardial infarct size and apoptosis after I/R, which was accompanied by enhanced phosphorylation of AMP-activated protein kinase (AMPK) and Akt in the ischemic heart. Fat-specific overexpression of human omentin also resulted in reduction of infarct size after I/R. Blockade of AMPK or Akt activity reversed omentin-induced inhibition of myocardial ischemic damage and apoptosis in mice. In cultured cardiomyocytes, omentin suppressed hypoxia/reoxygenation-induced apoptosis, which was blocked by inactivation of AMPK or Akt.ConclusionsOur data indicate that omentin functions as an adipokine that ameliorates acute ischemic injury in the heart by suppressing myocyte apoptosis through both AMPK- and Akt-dependent mechanisms
MRI Appearance of Prostatic Stromal Sarcoma in a Young Adult
Prostatic stromal sarcoma (PSS) is quite rare. Herein, we describe magnetic resonance imaging (MRI) features of a PSS identified in a 26-year-old man with dysuria and hematuria. MRI clearly depicted the extent and multinodular appearance of the tumor, which was mainly located in the central zone of the prostate. The tumor appeared as a heterogeneously signal-hyperintense mass with a pseudocapsule on T2-weighted imaging. Contrast-enhanced T1-weighted MRI showed necrotic portions in the gradually enhanced solid mass, and diffusion-weighted imaging permitted the accurate assessment of the local extent of the tumor. Thus, the appearance on MRI was quite different from that of adenocarcinoma of the prostate
Early Experience with MRI-ultrasound Fusion-guided Prostate Biopsy in Japanese Men with Elevated PSA Levels
Dynamics and GPR stratigraphy of a polar rock glacier on James Ross Island, Antarctic Peninsula
High b value (2,000 s/mm2) diffusion-weighted magnetic resonance imaging in prostate cancer at 3 Tesla: comparison with 1,000 s/mm2 for tumor conspicuity and discrimination of aggressiveness.
OBJECTIVE: The objective of our study was to investigate tumor conspicuity and the discrimination potential for tumor aggressiveness on diffusion-weighted magnetic resonance imaging (DW-MRI) with high b value at 3-T. MATERIALS AND METHODS: The institutional review board approved this study and waived the requirement for informed consent. A total of 50 patients with prostate cancer (69 cancer foci; 48 in the PZ, 20 in the TZ, and one in whole prostate) who underwent multiparametric prostate MRI including DW-MRI (b values: 0, 1000 s/mm2 and 0, 2000 s/mm2) on a 3-T system were included. Lesion conspicuity score (LCS) using visual assessment (1â=âinvisible for surrounding normal site; 2â=âslightly high intensity; 3â=âmoderately high; and 4â=âvery high) and tumor-normal signal intensity ratio (TNR) were assessed, and apparent diffusion coefficient (ADC, Ă10-3 mm2/s) of the tumor regions and normal regions were measured. RESULTS: Mean LCS and TNR at 0, 2000 s/mm2 was significantly higher than those at 0, 1000 s/mm2 (p<0.001 for both). In addition, ADC at both 0, 1000 and 0, 2000 s/mm2 was found to distinguish intermediate or high risk cancer with Gleason score â„7 from low risk cancer with Gleason score â€6 (p<0.001 for both). Furthermore, ADC of tumor regions correlated with Gleason score at both 0, 1000 s/mm2 (Ïâ=â-0.602; p<0.001) and 0, 2000 s/mm2 (Ïâ=â-0.645; p<0.001). CONCLUSIONS: For tumor conspicuity and characterization of prostate cancer on DW-MRI of 3-T MRI, bâ=â0, 2000 s/mm2 is more useful than bâ=â0, 1000 s/mm2
Author Correction: Gait improvement with wearable cyborg HAL trunk unit for parkinsonian patients: five case reports
Gait improvement with wearable cyborg HAL trunk unit for parkinsonian patients: five case reports
Abstract Cybernic treatment involves the generation of an interactive bio-feedback loop between an individualâs nervous system and the worn cyborg Hybrid Assistive Limb (HAL); this treatment has been applied for several intractable neuromuscular disorders. Thus, it is of interest to determine its potential for parkinsonian patients. This study confirmed the feasibility of using a HAL trunk unit to improve parkinsonian gait disturbance. HAL establishes functional and physical synchronization with the wearer by providing lateral cyclic forces to the chest in the form of somatosensory and motor cues. To confirm the feasibility of its use for improving parkinsonian gait disturbances, we conducted experiments with three Parkinsonâs disease patients and two patients with progressive supranuclear palsy. During the experiments, the immediate effect of the intervention was assessed; all participants exhibited improvements in gait disturbance while wearing the HAL unit, and this improvement effect persisted without the HAL unit in two participants. Afterward, based on the assessment, we conducted a continuous intervention for one participant. In this intervention, the number of steps in the final experiment was significantly decreased compared with the initial state. These findings suggest that the proposed method is an option for treating parkinsonian patients to generate somatosensory and motor cues
Qualitative and quantitative analyses of two b values protocols for lesion conspicuity of prostate cancer in the DW-MR image and ADC map.
<p>Data are given as mean±standard deviation. (LCS - lesion conspicuity score, TNR - tumor-normal signal intensity ratio).</p><p><sup>*</sup>Significant differences between bâ=â0 and 1000 s/mm<sup>2</sup> and bâ=â0 and 2000 s/mm.</p